Expanding Genome Accessibility Beyond SP-Cas9 Limitations Using Diverse Nuclease Platforms to Target Non-NGG PAM Sequences
- Addressing SP-Cas9 PAM sequence limitations that restrict targetability to only five percent of the human genome for conventional gene editing applications
- Leveraging diverse nuclease platforms recognizing alternative PAM sequences to expand genome accessibility and enable precise editing across previously inaccessible genomic regions
- Implementing next-generation CRISPR technologies including prime editors and base editors requiring PAM flexibility to achieve nucleotide-specific edits at desired genomic locations